Inhibikase Therapeutics, Inc. 8-K

What Happened
Inhibikase Therapeutics, Inc. (IKT) held its 2026 Annual Meeting of Stockholders on June 26, 2026 (virtual-only). At the meeting, shareholders approved an amendment to the company’s 2020 Equity Incentive Plan to increase the number of authorized common shares reserved for issuance by 3,000,000 shares. The amendment had been previously approved by the board and a summary was included in the company’s definitive proxy statement filed April 30, 2026. The full text of the amendment is attached as Exhibit 10.1 to the Form 8-K; the filing also includes a Certificate of Amendment to the company’s Amended and Restated Certificate of Incorporation (Exhibit 3.1).

Key Details

• Annual Meeting: June 26, 2026 (virtual-only via live webcast).
• 2020 Plan Amendment: increase of 3,000,000 shares reserved for issuance.
• Proxy summary filed: April 30, 2026 (definitive proxy statement).
• Exhibits on Form 8-K: Amendment No. 4 to the 2020 Equity Incentive Plan (Ex. 10.1) and Certificate of Amendment to the Amended and Restated Certificate of Incorporation (Ex. 3.1).

Why It Matters
Increasing the equity plan reserve gives the company capacity to grant additional stock awards for compensation, hiring or retention. That can help attract and retain employees and align management with shareholder interests, but it may also increase potential dilution for existing shareholders as additional shares are issued under the plan. Investors should review the plan amendment (Exhibit 10.1) and the proxy materials for details on grant terms and potential dilution.